Stocky turns companies like DAWNRAYS PHARMA into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. JD.com's 23% revenue growth and 18% ROIC reflect solid execution in Chinese e-commerce, but a Leadership Alignment score of 45/100 signals governance concerns—likely reflecting dispersed ownership and limited founder-CEO stakes—that constrain conviction. Regulatory headwinds in China remain a material overhang.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for DAWNRAYS PHARMA:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates DAWNRAYS PHARMA (2348.HK) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. JD.com's 23% revenue growth and 18% ROIC reflect solid execution in Chinese e-commerce, but a Leadership Alignment score of 45/100 signals governance concerns—likely reflecting dispersed ownership and limited founder-CEO stake
2348.HK's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 50/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for DAWNRAYS PHARMA yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
DAWNRAYS PHARMA scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for DAWNRAYS PHARMA covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 2348.HK — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 2348.HK in the app.
